rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
|
31811566 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines.
|
31706682 |
2020 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
|
31811566 |
2020 |
rs895819
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results suggested that rs895819 polymorphism was correlated with increased risk of colorectal cancer and breast cancer, but not all types of cancer.
|
31838252 |
2020 |
rs920778
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our findings imply that rs920778 polymorphism does not affect total cancer presence and the effect on specific cancer types is also weak in the Japanese population.
|
31759985 |
2020 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TP53 Arg72Pro (rs1042522 C > G) and miR-34b/c rs4938723 (T > C) polymorphisms have been known to modify cancer susceptibility.
|
31325764 |
2019 |
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single Nucleotide Polymorphisms (SNPs) of P53 Pro72Arg, MDM2 SNP309, P21 Ser31Arg, ER SNP594, HER2 Ile655Val, and FGFR2 rs2981582 have drawn attention as genetic factors associated with cancer risk.
|
31759353 |
2019 |
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Single Nucleotide Polymorphisms (SNPs) of P53 Pro72Arg, MDM2 SNP309, P21 Ser31Arg, ER SNP594, HER2 Ile655Val, and FGFR2 rs2981582 have drawn attention as genetic factors associated with cancer risk.
|
31759353 |
2019 |
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TP53 Arg72Pro (rs1042522 C > G) and miR-34b/c rs4938723 (T > C) polymorphisms have been known to modify cancer susceptibility.
|
31325764 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In serrated adenomas, BRAF-V600E mutation does not seem to be associated with age and sex, with the prevalence of dysplasia and cancer and with the morphology of the dysplastic component.
|
30815911 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reverse Phase Proteomic Array (RPPA, MD Anderson Cell Lines Project), RNAseq (Cancer Cell Line Encyclopedia) and vemurafenib sensitivity (Cancer Therapeutic Response Portal) data for BRAF-V600E cancer cell lines were curated.
|
31672130 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We previously repositioned the drug as the inhibitor of B-Raf V600E, but its anti-tumor effect in human cancer has never been reported.
|
30583070 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PGC1α-negative papillary cancer was associated with BRAF V600E mutation, large tumor size, extrathyroidal or lymphovascular invasion, lymph node metastasis, and advanced stage.
|
31333799 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell proliferation due to a modification of the ERK/MAPK-signal cascade.
|
31762942 |
2019 |
rs11614913
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<b>Conclusions:</b> The present meta-analysis suggests that mir-196a-2 rs11614913 may contribute to the risk of cancer especially in Asians.
|
30930933 |
2019 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Following drug resistance in patients with lung cancer treated by EGFR TKIs, a biopsy is required to obtain sufficient cancer tissue for T790M detection in order to select potential beneficiaries suitable for third-generation EGFR TKIs, such as osimertinib.
|
31407509 |
2019 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We reviewed all patients with T790M-positive NSCLC and acquired resistance to initial EGFR-TKIs who were administered osimertinib between March 2016 and January 2018 at the Tokyo Metropolitan Cancer and Infectious Diseases Center in Komagome Hospital, Japan.
|
31372272 |
2019 |
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is a genetic factor that has been associated with many pathologies, including cancer.
|
31170928 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In serrated adenomas, BRAF-V600E mutation does not seem to be associated with age and sex, with the prevalence of dysplasia and cancer and with the morphology of the dysplastic component.
|
30815911 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We previously repositioned the drug as the inhibitor of B-Raf V600E, but its anti-tumor effect in human cancer has never been reported.
|
30583070 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell proliferation due to a modification of the ERK/MAPK-signal cascade.
|
31762942 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PGC1α-negative papillary cancer was associated with BRAF V600E mutation, large tumor size, extrathyroidal or lymphovascular invasion, lymph node metastasis, and advanced stage.
|
31333799 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reverse Phase Proteomic Array (RPPA, MD Anderson Cell Lines Project), RNAseq (Cancer Cell Line Encyclopedia) and vemurafenib sensitivity (Cancer Therapeutic Response Portal) data for BRAF-V600E cancer cell lines were curated.
|
31672130 |
2019 |
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, we use the LITer gene circuit architecture to control gene expression of the cancer oncogene KRAS(G12V) and study its downstream effects through phospho-ERK levels and cellular proliferation.
|
31269201 |
2019 |
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
G12D and Q61H are among the most prevalent cancer-causing mutations at the P-loop and switch 2 regions of KRAS, respectively.
|
31554397 |
2019 |